Shanghai Henlius Biotech Debt 2024

Shanghai Henlius Biotech Aktienanalyse

What does Shanghai Henlius Biotech do?

Shanghai Henlius Biotech Inc. was founded in 2010 and has since focused on the development of innovative biopharmaceuticals. The company is headquartered in Shanghai, China and has additional locations in Taiwan, the USA, and Europe. The company has developed a wide portfolio of products that are manufactured based on monoclonal antibodies. These antibodies are produced in the human body and can recognize and attack diseased tissue, making them useful for the treatment of various diseases. Shanghai Henlius Biotech Inc.'s business model is based on an extensive research and development process, ranging from the discovery of a new drug to final product approval. The company utilizes advanced technologies and research facilities to develop innovative therapies. The company specializes in the development of biosimilars and novel biopharmaceuticals. Biosimilars are drugs that are structurally similar to already approved biopharmaceuticals but may differ in some characteristics, such as their precise molecular structure. The company has already launched several biosimilars on the market, including those for the treatment of gynecologic cancer, breast cancer, and rheumatoid arthritis. In addition to biosimilars, the company also focuses on the development of novel biopharmaceuticals. These drugs are typically used for the treatment of rare diseases or cancer where there are limited treatment options available. The company has developed several such products, including antibodies for the treatment of lung cancer and bladder cancer. Shanghai Henlius Biotech Inc. has successfully established itself in the Chinese market in recent years but also operates internationally. The company has partnerships with numerous companies in Asia, Europe, and the USA to distribute its products worldwide. Partners include well-known names such as Accord Healthcare, Sandoz, and Pfizer. Overall, Shanghai Henlius Biotech Inc. is a leading player in the biotechnology industry. The company specializes in the development of high-quality biopharmaceuticals and has the capability to develop and bring innovative therapies to the market. Its business model is based on extensive research and development processes, allowing the company to be innovative and successful in a highly competitive market. Shanghai Henlius Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Shanghai Henlius Biotech's Debt Structure

Shanghai Henlius Biotech's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Shanghai Henlius Biotech's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Shanghai Henlius Biotech’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Shanghai Henlius Biotech’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Shanghai Henlius Biotech stock

What is the debt of Shanghai Henlius Biotech this year?

Shanghai Henlius Biotech has a debt level of 3,105.39 CNY this year.

What was the debt of Shanghai Henlius Biotech compared to the previous year?

The debt of Shanghai Henlius Biotech has increased by 3.63% compared to the previous year increased.

What are the consequences of high debt for investors in Shanghai Henlius Biotech?

High debt can pose a risk for investors of Shanghai Henlius Biotech, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Shanghai Henlius Biotech?

Low debt means that Shanghai Henlius Biotech has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Shanghai Henlius Biotech affect the company?

An increase in debt of Shanghai Henlius Biotech can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Shanghai Henlius Biotech affect the company?

A reduction in debt of Shanghai Henlius Biotech can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Shanghai Henlius Biotech?

Some factors that can influence the debt of Shanghai Henlius Biotech include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Shanghai Henlius Biotech so important for investors?

The debts of Shanghai Henlius Biotech are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Shanghai Henlius Biotech take to change the debt?

To change the debt, Shanghai Henlius Biotech can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Shanghai Henlius Biotech pay?

Over the past 12 months, Shanghai Henlius Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shanghai Henlius Biotech is expected to pay a dividend of 0 CNY.

What is the dividend yield of Shanghai Henlius Biotech?

The current dividend yield of Shanghai Henlius Biotech is .

When does Shanghai Henlius Biotech pay dividends?

Shanghai Henlius Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Shanghai Henlius Biotech?

Shanghai Henlius Biotech paid dividends every year for the past 0 years.

What is the dividend of Shanghai Henlius Biotech?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Shanghai Henlius Biotech located?

Shanghai Henlius Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shanghai Henlius Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shanghai Henlius Biotech from 8/1/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 8/1/2024.

When did Shanghai Henlius Biotech pay the last dividend?

The last dividend was paid out on 8/1/2024.

What was the dividend of Shanghai Henlius Biotech in the year 2023?

In the year 2023, Shanghai Henlius Biotech distributed 0 CNY as dividends.

In which currency does Shanghai Henlius Biotech pay out the dividend?

The dividends of Shanghai Henlius Biotech are distributed in CNY.